

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Please cancel claim 34.

1-3. (Canceled)

4. (Currently Amended) A method of alleviating ~~a disease or disorder~~ reentry atrial flutter in an affected animal cell, said method comprising locally delivering to ~~the~~ a cardiac cell a reverse gene therapy vector comprising a promoter operably linked with a nucleic acid encoding a therapeutic gene product which is usually only expressed in cells of an abnormal tissue that is not afflicted with ~~the disease or disorder~~ reentry atrial flutter, wherein said therapeutic gene product is a defective HERG protein, and delivery of said vector to the affected cardiac cell alleviates ~~the disease or disorder~~ flutter.

5. (Previously Presented) The method of claim 4, wherein the defective HERG protein is selected from the group consisting of HERG (A561V) protein and MIRP protein.

6-15. (Canceled)

16. (Previously Presented) The method of claim 4, wherein the promoter is a cardiac tissue specific promoter.

17. (Original) The method of claim 16, wherein the cardiac tissue-specific promoter is selected from the group consisting of

the ANF promoter and the  $\alpha$ -MyHC promoter.

18-30. (Canceled)

31. (Previously Presented) The method of claim 4, wherein the cell is a myocardial cell.

32. (Original) The method of claim 31, wherein the cell is a right atrial myocardium cell.

33. (Previously Presented) The method of claim 31, wherein the cell is a cell of the crista terminalis.

34-35. (Canceled)

36. (Currently Amended) The method of claim 34 31, wherein the defective HERG protein is HERG (A561 V) protein.

37. (Original) The method of claim 36, wherein the promoter is a cardiac tissue-specific promoter.

38. (Original) The method of claim 37, wherein the cardiac tissue-specific promoter is selected from the group consisting of the ANF promoter and the  $\alpha$ -MyHC promoter.

39-64. Canceled.

65. (Previously Presented) The method of claim 5, wherein the defective HERG protein is MIRP protein.

66. (Canceled)

67. (Previously Presented) The method of claim 65, wherein the promoter is cardiac tissue-specific promoter.

68. (Previously Presented) The method of claim 67, wherein the cardiac tissue-specific promoter is selected from the group consisting of the ANF promoter and the  $\alpha$ -MyHC promoter.

69-70. (Canceled)